ViewRay Stock Surges 2400% on XETRA as MRI Cancer Therapy Demand Grows

ViewRay, Inc. (6L9.F) delivered a stunning 2400% surge on XETRA, with shares climbing to €0.025 from €0.001 in a single session. The medical device maker, headquartered in Oakwood, Ohio, designs and manufactures MRI-guided radiation therapy systems for cancer treatment. This explosive move reflects renewed investor interest in the company’s MRIdian platform, which addresses critical challenges in precision oncology. Trading volume reached 3,500 shares, significantly above the 279-share average, signaling strong conviction behind the rally.

6L9.F Stock Price Action and Technical Setup

The €0.025 price level represents a critical breakout for 6L9.F stock after months of consolidation near penny-stock levels. Shares now trade well above the 50-day average of €0.319 and dramatically below the 200-day average of €2.717, reflecting the stock’s severe long-term decline. However, today’s explosive volume and price action suggest a potential reversal pattern emerging.

The stock’s year-to-date performance remains deeply negative at -99.4%, with the 52-week high of €4.60 now seeming distant. Yet the 52-week low of €0.0005 shows just how oversold 6L9.F had become before this rally. Relative volume spiked to 12.5x normal levels, indicating institutional or significant retail accumulation at these depressed valuations.

ViewRay’s MRIdian Platform and Market Opportunity

ViewRay manufactures the MRIdian system, an advanced MRI-guided radiation therapy platform that combines real-time imaging with precision treatment delivery. This technology addresses three critical clinical problems: beam distortion in traditional systems, skin toxicity from radiation exposure, and treatment accuracy limitations. The company serves university hospitals, community cancer centers, private practices, and government institutions across the United States, France, Taiwan, and the United Kingdom.

With 2,950 full-time employees and a direct sales force, ViewRay operates in the high-growth medical devices sector within healthcare. The global precision oncology market continues expanding as hospitals invest in advanced treatment technologies. Track 6L9.F on Meyka for real-time updates on this emerging recovery story.

Financial Metrics and Valuation Reality Check

Despite today’s rally, 6L9.F stock faces significant financial headwinds. The company reported a negative EPS of -€0.55 and operates at a loss with a net profit margin of -105%. Market capitalization stands at €207.2 million, while the price-to-sales ratio of 2.36x appears reasonable only if revenue stabilizes. Free cash flow per share is negative at -€0.529, indicating the company burns cash operationally.

The current ratio of 2.36x suggests adequate short-term liquidity, with €0.752 cash per share available. However, debt-to-equity of 1.05x and negative return on equity of -85% highlight operational challenges. Meyka AI rates 6L9.F with a grade of C+, suggesting a HOLD stance. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Why 6L9.F Stock Exploded Today

The 2400% surge likely reflects a combination of technical factors: extreme oversold conditions, low float at penny-stock levels, and potential short covering. With shares trading near 52-week lows, any positive catalyst or algorithmic buying can trigger explosive moves in thinly traded stocks. The 12.5x relative volume spike confirms this wasn’t random price action.

Investors should note that ViewRay remains unprofitable and cash-flow negative, meaning this rally may represent a technical bounce rather than fundamental improvement. The healthcare sector itself is performing well on XETRA, with an average PE of 29.4x and strong year-to-date gains. However, 6L9.F’s specific challenges—losses, negative cash flow, and massive historical decline—require careful monitoring before committing capital.

Final Thoughts

ViewRay’s 2400% surge to €0.025 on XETRA captures the volatility inherent in deeply distressed medical device stocks. While the MRIdian platform addresses real clinical needs in precision oncology, the company’s persistent losses, negative cash flow, and debt burden remain serious concerns. Today’s explosive move likely reflects technical oversold conditions and short covering rather than fundamental recovery. Investors should demand clear evidence of revenue growth, path to profitability, and positive cash flow before treating this rally as a sustainable turnaround. The healthcare sector offers better-capitalized alternatives with proven business models.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.